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Background: TG6, a brain expressed transglutaminase, is implicated in the neurological manifestations of celiac
disease (CD). We hypothesized that earlier brain injury due to head trauma may be more common in patients with
CD, potentially through trauma-induced TG6 leading to interaction with TG2.
Methods: Through biopsy reports from all 28 pathology departments in Sweden we identified 29,096 individuals
with CD (in this study defined as villous atrophy). We then examined the risk of earlier head trauma in CD
compared to the risk in 144,522 controls matched for age, sex, county and calendar year. Odds ratios (ORs) were
calculated using conditional logistic regression.
Results: 981 (3.4%) individuals with CD and 4,449 (3.1%) controls had a record of earlier head trauma. Individuals
with head trauma were hence at a 1.10-fold increased risk of future CD (95% CI = 1.02-1.17). ORs were independent
of sex or age at CD. The highest risk of future CD was seen during the first year after trauma. There was no
association between severity of trauma and risk of developing CD.
Conclusions: This study found a very small excess risk for future CD in individuals with an earlier head trauma.
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Celiac disease (CD) occurs in about 1% of the population
in Western Europe [1]. It is a multi-faceted disorder
sometimes characterized by neurological manifestations
such as gluten ataxia, [2] peripheral neuropathy [3,4],
headache with white matter abnormalities, [5] and
possibly also epilepsy [6,7]. Patients with gluten ataxia
have positive serum antigliadin antibodies, but may not
always have small intestinal enteropathy.
Our research has shown that a large proportion of
individuals with gluten ataxia show increased levels of
tissue transglutaminase 6 (TG6) [8,9]. Although TG6
originates in the brain, it has also been detected in the
small intestinal mucosa, and can interact with TG2. It is
capable of deamidating gliadin and it is gluten depend-
ant [10].
CD is a lifelong small intestinal immune-mediated
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distribution, and reproduction in any mediumatrophy (VA). It occurs in about 1% of the Western
population, and requires lifelong treatment with gluten-
free diet. The overwhelming majority of individuals with
CD are DQ2+ or DQ8+, but even if genetic studies have
shown a high concordance rate of CD in monozygotic
twins [11], genetic factors alone cannot explain the eti-
ology of CD. In addition to the mandatory exposure to
gluten, short breast-feeding [12,13], infections [13], cae-
sarean section [14,15] and lack of smoking [16] have
been implicated in the pathogenesis of CD. However
much of earlier research on CD risk factors has actually
shown contradicting data, and many of the positive find-
ings have only been seen in small children with CD
while the majority of individuals with CD are nowadays
diagnosed in adulthood [17-19].
The aim of this study was to examine if individuals
with head trauma leading to brain injury were at in-
creased risk of developing CD. We hypothesized that
head trauma and secondary cerebral and cerebellar in-
sult may trigger autoimmunity against TG6 which in
turn may lead, in genetically susceptible individuals, to
the development of CD.e BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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We used data from small intestinal biopsy reports
obtained from all 28 pathology departments in Sweden
to identify individuals with CD. Biopsy data were then
linked to inpatient and hospital-based outpatient data on
head trauma through the unique Personal Identity
Number assigned to all Swedish residents [20].
Exposure - Head trauma
We defined head trauma (skull fractures and intracranial
injury) as having a relevant international classification of
disease (ICD) code in the Swedish Patient Register
(ICD7: 800–4 and 851–55; ICD8: 800–4 and 850–54;
ICD9: 800–4 and 850–54; and ICD10: S02 (minus S02.5)
and S06). A recent validation found that the most
common criteria for assigning an ICD code for head
trauma in Sweden are loss of consciousness (76%) and
posttraumatic amnesia (38%) [21].
The data source for head trauma, the Swedish Patient
Register began in 1964 (then exclusively inpatient care)
[22]. The coverage reached 75% of the Swedish popula-
tion in the beginning of the 1980s, and the register be-
came nationwide in 1987 [22]. Since 2001 the register
also includes hospital-based outpatient visits.
Outcome measure - Celiac disease
We collected data on VA (histopathology stage Marsh 3)
[23] from computerized biopsy reports from all 28
Swedish pathology departments. The duodenal/jejunal
biopsies had been performed between 1969 and 2008,
but our data collection took place 2006–08. Searches for
biopsy reports were carried out by local IT personnel
who delivered data on personal identity number, morph-
ology (for a list of relevant morphology codes according
to the Swedish SnoMed system [19]), topography
(duodenum or jejunum), and date of biopsy. Among 114
randomly selected individuals with VA undergoing
patient chart validation, 108 (95%) had CD [19]. Biopsy
reports were on average based on three tissue specimen
[24] (and this should rule in about 95% of all CD [25]).
Controls
Each individual with CD was matched with up to 5 con-
trols for age, sex, county, and calendar year. Controls
were sampled from individuals without a previous small
intestine biopsy, and identified through the Swedish
Total population register. Control matching was carried
out by the government agency Statistics Sweden. After
removal of duplicates and other data irregularities, our
data-set was identical to that of our previous paper on
mortality in CD [26]. The main analysis of this paper
was hence based on 29,096 individuals with CD and
144,522 matched controls.Statistics
Conditional logistic regression was used to calculate
odds ratios (ORs) for later CD in individuals with head
trauma. We used a conditional approach; meaning that
each individual with CD was first compared only to his/
her matched controls within the same stratum. This
eliminated the effect of age, sex, county and calendar
year on our risk estimate. We then summarized
stratum-specific data and calculated an overall OR for
future CD.
A priori sub-analyses were carried out and included
ORs according to sex, age and calendar period at CD
diagnosis. We also examined the risk of CD according
to time since head trauma (<1, 1–4.99, and ≥5 years).
In a sub-analysis we adjusted for country of birth
(Nordic vs. not Nordic) and education according to
four priori-defined categories [27]. Some 4% of individ-
uals had no data on education and were fitted into a
separate fifth category in the multivariate analysis.
In another analysis we examined head traumas occur-
ring in adults (>19 years of age) and risk of future CD.
We did so hypothesizing that non-nutritional risk factors
may be especially important for adulthood CD.
We performed three sensitivity analyses. In two of
these we examined the association between severe head
trauma and CD. We defined severe head trauma as
requiring either a) inpatient care in a neurosurgery
department or b) ≥3 days of inpatient care. To increase
the specificity of our exposure variable we also
calculated the OR for CD in individuals with at least
two prior records of head trauma (third analysis).
We used SPSS 18 (SPSS, Inc. Chicago, IL, USA) for
all analyses. ORs with 95% confidence intervals that
did not include one were regarded as statistically
significant.Ethics
The current study was approved by the Ethics Review
board of Stockholm, Sweden, which deemed that no in-
dividual informed consent was required since data were
strictly register-based.Results
Background data
The majority of the study participants were female
(Table 1). The median age at diagnosis with CD was
30 years (range 0–95 years), and individuals had been di-
agnosed between 1969 and 2008 (median year: 1998).
Some 96.7% of individuals with CD were born in the
Nordic countries, compared to 94.3% of the controls.
The median age at first head trauma in individuals with
later CD was 18 years (range 0–92 years).





Total, n 29,096 144,522
Females, n (%) 18,005 (61.9) 89,544 (62.0)
Males, n (%) 11,091 (38.1) 54,978 (38.0)
Agea 0–19 years, n (%) 11,802 (40.6) 58,852 (40.7)
Age 20–39, n (%) 5,312 (18.3) 26,385 (18.3)
Age 40–59, n (%) 6,477 (22.3) 32,254 (22.3)
Age ≥60, n (%) 5,505 (18.9) 27,031 (18.7)
Calendar yeara
−1989, n (%) 4,105 (14.1) 20,378 (14.1)
1990-99, n (%) 12,059 (41.4) 59,874 (41.4)
2000-, n (%) 12,932 (44.4) 64,270 (44.5)
Data on head trauma
Head trauma,b n (%) 981 (3.4) 4,449 (3.1)
Age at first head trauma,
years (median, range)
18; 0–92 19; 0-92
aAt time of celiac disease diagnosis.
bBefore diagnosis of celiac disease and matching date in controls.
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Of 29,096 individuals with CD, 981 (3.4%) had a record
of earlier head trauma compared to 4,449/144,522 (3.1%)
controls. The OR for future CD in individuals with head
trauma was 1.10 (95% CI = 1.02-1.17). Adjustment for
education and country of birth did not affect the risk
estimates (data not shown).
The highest risk for future CD was seen in the first
year after head trauma (OR = 1.35; 95% CI = 1.10-1.66),
with decreasing ORs thereafter (1–4.99 years: 1.21; 95%
CI = 1.05-1.38). No association was seen between headTable 2 Head trauma and risk of later Celiac disease
Subgroup Head traumas, N (%)
Celiac disease Controls
Sex
Males 465 (4.2) 2,189 (4.0)
Females 516 (2.9) 2,260 (2.5)
Agea
<20 yrs 294 (2.5) 1,245 (2.1)
20-39 yrs 292 (5.5) 1,315 (5.0)
40-59 yrs 229 (3.5) 1,062 (3.3)
60+ yrs 166 (3.0) 827 (3.1)
Calendar perioda
−1989 77 (1.9) 256 (1.3)
1990-1999 344 (2.9) 1,589 (2.7)
2000-2008 560 (4.3) 2,604 (4.1)
aAt time of celiac disease diagnosis.trauma and future CD ≥5 years after the trauma (OR =
1.02; 95% CI = 0.94-1.11).
The OR for future CD was similar in males and fe-
males, but only in females did the association reach stat-
istical significance (OR = 1.13) (Table 2). Head trauma in
childhood increased the risk of having a later CD diag-
nosis in childhood (OR = 1.17; 95% CI = 1.03-1.32). Head
trauma was actually associated with an increased risk of
future CD in all age categories except for in the oldest
age category where the association was neutral (Table 2).
There was no difference in risk estimates according to
calendar period (p for interaction: 0.099) (Table 2).
Restricting our analysis to head traumas occurring in
adults we found a small excess risk of later CD (OR =
1.10; 95% CI = 1.03-1.18).
Sensitivity analyses
We found no statistically significant associations be-
tween CD and head trauma, when we restricted our
exposure to severe head trauma defined as either requir-
ing inpatient care in a neurosurgery department (OR =
0.77; 95% CI = 0.51-1.16), or ≥3 days of any inpatient
care (OR = 1.10; 95% CI = 0.96-1.27) (Table 3).
Having at least two records of head trauma was not
associated with later CD (OR = 1.02; 95% CI = 0.86-1.20).
Data from stratified analyses are given in Table 3.
Discussion
In this nationwide case–control study we examined the
association between head trauma and CD. Given the role
of TG6 in the pathophysiology of gluten ataxia and its
abundance in brain tissue, we hypothesized that head
trauma resulting in cerebral and cerebellar insults may
trigger autoimmunity against TG6 which in turn may
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nificantly increased risk of CD in individuals with
previous head trauma.
TG6, TG2 (the autoantigen in CD) and TG3 (the
autoantigen in dermatitis herpetiformis) share genetic,
structural and enzymatic properties. It has been shown
that patients with gluten ataxia have an immunological
response primarily directed against TG6 even in the ab-
sence of enteropathy [8]. The interplay between these 3
types of transglutaminases during disease state is not yet
known. What is known is that not all patients with CD
are positive for TG3 or TG6 and not all patients with
gluten ataxia are positive for TG2 or TG3. As these 3
transglutaminases have a 65% homology, are gluten de-
pendants and are capable of deamidating gluten it is
plausible that the development of autoimmunity to one
may lead to the development of autoimmunity to the
others perhaps through a process of epitope spreading.
In gluten ataxia, there is evidence of IgA deposits against
TG6 in the cerebellum [8]. TG6 autoantibodies have
been thought to be a more specific marker for the
neurological manifestations (in particular gluten ataxia),
with the median TG6 antibody concentration being sig-
nificantly higher than TG2 antibody in such patients.
During brain injury self epitopes (e.g. TG6), which are
normally shielded from the systemic immune system,
may become exposed to adaptive immunity. This may
result in the immune system reacting to self-antigens














OR; 95% CI OR; 95% CI OR; 95% CI
Overall 0.77; 0.51-1.16 1.10; 0.96-1.27 1.02; 0.86-1.20
Sex
Males 0.84; 0.51-1.39 1.04; 0.85-1.26 0.77; 0.60-0.99
Females 0.65; 0.32-1.34 1.19; 0.96-1.46 1.38; 1.09-1.75
Agea
<20 yrs 0.57; 0.14-2.40 1.18; 0.67-2.18 1.29; 0.93-1.79
20-39 yrs 0.25; 0.06-1.01 1.07; 0.79-1.44 0.84; 0.60-1.19
40-59 yrs 0.90; 0.41-1.98 1.17; 0.93-1.48 1.04; 0.74-1.46
60+ yrs 1.07; 0.61-1.90 1.04; 0.82-1.33 0.94; 0.66-1.35
Calendar
perioda
−1989 0.84; 0.19-3.65 1.59; 1.06-2.37 1.33; 0.69-2.56
1990-1999 0.58; 0.27-1.25 1.01; 0.81-1.26 0.86; 0.62-1.20
2000-2008 0.89; 0.53-1.50 1.09; 0.89-1.35 1.06; 0.86-1.31
aAt time of celiac disease diagnosis.autoimmunity. One study has demonstrated the pres-
ence of intrathecal antibodies against transglutaminases
in the cerebrospinal fluid of patients with neurological
dysfunction [28]. After brain injury, brain specific anti-
gens can be measured in the serum implying that such
antigens can gain access into the systemic circulation
and are not restricted by the blood–brain barrier [29].
We are not aware of any earlier study that has exam-
ined if head trauma could trigger CD. In CD diagnosed
in early childhood, nutritional factors are likely to play
an important role in the CD pathogenesis, while less is
known with regards to adulthood CD. Risk factors may
exert different degrees of influence depending on the
age of the individual. Due to the large statistical power
of our study we were able to perform age-stratified ana-
lyses, but also specifically analyze the impact of head
trauma in adulthood. Odds ratios were similar in all
these analyses except for a lack of association among in-
dividuals aged ≥60 years at CD diagnosis. The lack of as-
sociation between head trauma and CD in this age
stratum could be due to limitations of the Swedish Pa-
tient Register. Although this register has nationwide
coverage since 1987, and began in 1964 it will not have
covered the childhood or adolescence (when some will
have had head trauma) of many of those individuals di-
agnosed with CD ≥ 60 years. This is also obvious from
Table 2 where the proportion of individuals with a rec-
ord of prior head trauma in this age-group is lower than
among younger adults. The median age at first head
trauma was 18 years.
Although the association between head trauma and
later CD was only statistically significant in women, we
found no statistical heterogeneity between men and
women. While ORs were not statistically significantly
different between calendar periods there was a trend to-
wards a higher OR before 1990. One explanation for this
could be the lower awareness of CD in the 1970s and
1980s, allowing surveillance bias after head trauma to
play a greater role for the detection of CD in these years.
We ascertained CD through biopsy data. This in-
formed us about the exact date of CD diagnosis, but we
have no data on the exact date of CD onset. Many indi-
viduals go undiagnosed for several years [30], and such
misclassification may have affected our ORs. We did not
screen study participants for CD, and can therefore not
confirm or reject an association between head trauma
and positive serology (including positive IgA gliadin
antibodies) in individuals who did not contact health
care. However the threshold for attending health care is
low in Sweden since virtually all health care is publicly
funded and virtually free of charge. However, a large
proportion of individuals with CD remain undiagnosed
[31], and we cannot rule out that the association with
head trauma is restricted to clinically manifest CD.
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than CD [19]. When we manually examined more than
1500 biopsy reports with VA or inflammation, the most
common non-celiac diagnosis mentioned in the biopsy
reports was IBD constituting only 0.3% of the records.
The most common symptoms in a subset of randomly
selected individuals with CD were diarrhea (36%) and
anemia (35%) [19] Biopsy reports with VA are also likely
to have a high sensitivity for diagnosed CD since 96-100
% of all gastroenterologists and pediatricians in Sweden
perform a biopsy before CD diagnosis [19].
We used ICD codes to identify head trauma. Bellner
et al. have shown that 91% of Swedish hospitals man-
aging head injuries use the ICD-10 code “SO6” to code
head trauma [21]; and we used the same ICD-9 codes as
in a previous Swedish study on head trauma [32].
In order to increase the specificity of our exposure
variable, we carried out several sensitivity analyses.
These analyses showed inconsistent results with one
showing a negative association, a second a positive asso-
ciation, and a third a neutral association between head
trauma and CD. The 95% CIs of the three analyses did
however overlap and it should be noted that head
trauma requiring health care in a neurosurgery depart-
ment, indicating severe head trauma did not show an as-
sociation with future CD (OR = 0.77). This observation,
however does not necessarily argue against our hypoth-
esis because the severity of the insult to the brain may
not correlate with the likelihood of the development of
autoimmunity to TG6. Furthermore patients with head
injury that are admitted to neurosurgical units are very
likely to receive steroids as a means of reducing swelling
secondary to the head injury. Steroids are known to
interfere with the immune response.
Another explanation for the small increased risk of
CD in our main analysis is surveillance bias. The highest
ORs were seen in the first year after head trauma, and
after that ORs went down towards 1. Head trauma can
have long-term consequences including posttraumatic
headache, necessitating regular health care contact
where a CD may have been discovered only because the
patient met with a physician for another reason (head
trauma). However we cannot altogether rule out that the
10% excess risk of CD seen in this study is true, since it
is consistent with our a-priori hypothesis. The observa-
tion that the highest ORs were seen in the first year after
head trauma would be consistent with the timescale of
an autoimmune response triggered by the monophasic
event of head trauma without any chronic ongoing insult
to the brain, but may also be due to increased testing for
a number of diagnoses (including CD) in patients with
brain trauma necessitating hospital contact.
Finally, our earlier research has shown that CD is
associated with a number of other immune-mediateddiseases [33-35] and such comorbidity, if linked to
prior head trauma, may also have influenced our risk
estimates.
Conclusions
In conclusion, we found a small increased risk of CD in
individuals with earlier head trauma. This excess risk
may be due to surveillance bias or due to an auto-
immune response against transglutaminases triggered by
the brain injury.
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